Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

U.S. stocks finished Friday higher as investors looked past elevated Treasury yields and continued to support technology and AI-linked shares. The ...

The Week That Was, The Week Ahead: Macro and Markets, September 27

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) has completed a Phase 1 stu...

BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline

In a report released on September 21, Trung Huynh from RBC Capital maintained a Hold rating on Bristol-Myers Squibb, with a price target of $64.00....

RBC Capital Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

RBC Capital analyst Trung Huynh maintained a Hold rating on Bristol-Myers Squibb yesterday and set a price target of $64.00. According to TipRanks,...

Insiders have been trading these 5 stocks: (($SNOW)), (($AMAT)), (($DELL)), (($ZM)) and (($BMY)). Here is a breakdown of their recent trades and th...

Snowflake, Applied Materials, Dell, Zoom, Bristol-Myers Insider Shock

In a report released on September 9, Trung Huynh from RBC Capital maintained a Hold rating on Bristol-Myers Squibb, with a price target of $64.00. ...

RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is running a late stage study that pi...

BMY Targets Pediatric MS Edge With New Ozanimod Study Against Fingolimod

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) has completed a long-term P...

Bristol-Myers Squibb’s Long-Term Psoriasis Study Brings Fresh Data for BMY Investors

ONO Pharmaceutical Co ($OPHLF), Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb and O...

Bladder Cancer Trial Completion Puts Opdivo in Focus for BMY and Ono Investors

Scotiabank analyst Louise Chen maintained a Hold rating on Bristol-Myers Squibb today and set a price target of $60.00. According to TipRanks, Chen...

Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY), Stryker (SYK) and Inno...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY), Stryker (SYK) and InnovAge Holding (INNV)

In a report released today, from Berenberg Bank reiterated a Buy rating on Bloomsbury Publishing, with a price target of p825.00. Currently, the an...

Berenberg Bank Sticks to Its Buy Rating for Bloomsbury Publishing (BMY)

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company (BMY) is launching a Phase 2 ...

Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial

RBC Capital Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS). Bris...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$63.45	-0.67%	3.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$63.45	-0.7%	3.12M
3
4
5
6

BMY

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel